<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288937</url>
  </required_header>
  <id_info>
    <org_study_id>AAAF3404</org_study_id>
    <nct_id>NCT01288937</nct_id>
  </id_info>
  <brief_title>A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain</brief_title>
  <official_title>A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 11-week randomized, double-blind, placebo-controlled trial of Milnacipran 100 mg/d&#xD;
      in patients with idiopathic neuropathic pain. Milnacipran, a dual norepinephrine and&#xD;
      serotonin reuptake inhibitor has been a safe and beneficial treatment for patients with&#xD;
      fibromyalgia and may be useful to treat patients with painful peripheral neuropathy.&#xD;
&#xD;
      The primary outcome will be assessed by the change in daily averaged weekly 0-10 pain&#xD;
      intensity score, from baseline to week 9, by intention to treat analysis. The same analysis&#xD;
      will be used on several secondary measures including daily averaged weekly 0-10 pain&#xD;
      intensity score the sleep interference scale and the Rand-36 quality of life scale.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Milnacipran helps serotonin and noradrenaline work more effectively on the central nervous&#xD;
      system. Serotonin and noradrenaline are molecules made by the brain that affect how your body&#xD;
      responds to pain. Milnacipran, a dual norepinephrine and serotonin reuptake inhibitor has&#xD;
      been a safe and beneficial treatment for patients with fibromyalgia and may be useful to&#xD;
      treat patients with painful peripheral neuropathy. Many clinical trials for neuropathy pain&#xD;
      are done in patients with diabetic neuropathy. Idiopathic neuropathy however, is a common&#xD;
      cause of neuropathy and accounts for 25% of all neuropathies, and over 50% of small fiber&#xD;
      neuropathies. The information in this study will provide information on whether milnacipran&#xD;
      also provide benefit as a medication for neuropathic pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">April 5, 2011</start_date>
  <completion_date type="Actual">December 23, 2014</completion_date>
  <primary_completion_date type="Actual">October 22, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Likert Pain Scale Score</measure>
    <time_frame>Baseline, 9 weeks</time_frame>
    <description>The Likert Pain Scale Score is a psychometric scale commonly involved in research that employs questionnaires to measure the intensity of pain. It is used to determine the level of pain for research participants. The minimum score of 0 indicates &quot;no pain&quot; which is the better score and the maximum and total score of 10 indicates the &quot;the worst possible pain&quot; which is the worse outcome . Scores 1-3= Mild, scores 4-6= Moderate, scores 7-10= Severe. It is the most widely used approach to scaling responses in survey research. Patients will fill out a pain diary from baseline to end of treatment. This will be used to assess if there was a reduction in pain of the daily averaged weekly 0-10 pain scale at week 9 compared to the baseline. The Unit of Measure is the scores on the scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Idiopathic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Milnacipran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Milnacipran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):&#xD;
Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)</description>
    <arm_group_label>Milnacipran</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients age 18 to 80 years&#xD;
&#xD;
          -  Patients with signs and symptoms of a peripheral neuropathy, with either abnormal&#xD;
             nerve conductions or abnormal epidermal nerve fiber density with neuropathic pain.&#xD;
&#xD;
          -  Pain will have been present for at least 6 months&#xD;
&#xD;
          -  Patients may be on other medications for neuropathic pain (eg, antiepileptic&#xD;
             medications, opiates or non steroidal antiinflammatories)Í¾ however they must be on a&#xD;
             stable dose for 4 weeks prior to, with no plan to change during the study&#xD;
&#xD;
          -  All patients must have had a normal fasting glucose or B12, thyroid stimulating&#xD;
             hormone, and serum protein electrophoresis, since the onset of their symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other cause of neuropathy (eg, diabetic neuropathy, toxic neuropathy, HIV neuropathy,&#xD;
             celiac neuropathy, inherited neuropathy)&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Use of another serotonin and norepinephrine reuptake inhibitors (eg, duloxetine,&#xD;
             venlafaxine), tricyclic antidepressants, monoamine oxidase inhibitors (MAOI) or&#xD;
             selective serotonin reuptake inhibitors&#xD;
&#xD;
          -  Myocardial infarction stroke or life threatening arrhythmia within the last 6 months&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Hepatic or renal failure&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  narrow angle glaucoma&#xD;
&#xD;
          -  History of epilepsy or a seizure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas H Brannagan III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <results_first_submitted>March 14, 2017</results_first_submitted>
  <results_first_submitted_qc>August 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Thomas Brannagan</investigator_full_name>
    <investigator_title>Professor of Clinical Neurology</investigator_title>
  </responsible_party>
  <keyword>Milnacipran</keyword>
  <keyword>Idiopathic Peripheral Neuropathy</keyword>
  <keyword>Diabetic neuropathy</keyword>
  <keyword>Neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
    <mesh_term>Levomilnacipran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients will be recruited from the practices of the investigators of the peripheral neuropathy center. These subjects will already be receiving treatment in the clinics and private practices of neurologists at the Neurological Institute.&#xD;
Patients will also be recruited from physician referrals and advertising.</recruitment_details>
      <pre_assignment_details>Prior to randomization, subjects are assessed at baseline with neurological examinations, physical examination and pain questionnaire/diary.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Milnacipran</title>
          <description>Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):&#xD;
Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Milnacipran</title>
          <description>Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):&#xD;
Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Likert Pain Scale Score</title>
        <description>The Likert Pain Scale Score is a psychometric scale commonly involved in research that employs questionnaires to measure the intensity of pain. It is used to determine the level of pain for research participants. The minimum score of 0 indicates &quot;no pain&quot; which is the better score and the maximum and total score of 10 indicates the &quot;the worst possible pain&quot; which is the worse outcome . Scores 1-3= Mild, scores 4-6= Moderate, scores 7-10= Severe. It is the most widely used approach to scaling responses in survey research. Patients will fill out a pain diary from baseline to end of treatment. This will be used to assess if there was a reduction in pain of the daily averaged weekly 0-10 pain scale at week 9 compared to the baseline. The Unit of Measure is the scores on the scale.</description>
        <time_frame>Baseline, 9 weeks</time_frame>
        <population>For the milnacipran arm, 4 subjects were enrolled; however, 1 subject did not complete the study (due to AE: stomach pain) and was not included in the outcome measure data collection/analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):&#xD;
Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period).</description>
          </group>
        </group_list>
        <measure>
          <title>Likert Pain Scale Score</title>
          <description>The Likert Pain Scale Score is a psychometric scale commonly involved in research that employs questionnaires to measure the intensity of pain. It is used to determine the level of pain for research participants. The minimum score of 0 indicates &quot;no pain&quot; which is the better score and the maximum and total score of 10 indicates the &quot;the worst possible pain&quot; which is the worse outcome . Scores 1-3= Mild, scores 4-6= Moderate, scores 7-10= Severe. It is the most widely used approach to scaling responses in survey research. Patients will fill out a pain diary from baseline to end of treatment. This will be used to assess if there was a reduction in pain of the daily averaged weekly 0-10 pain scale at week 9 compared to the baseline. The Unit of Measure is the scores on the scale.</description>
          <population>For the milnacipran arm, 4 subjects were enrolled; however, 1 subject did not complete the study (due to AE: stomach pain) and was not included in the outcome measure data collection/analysis.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.1" upper_limit="8"/>
                    <measurement group_id="O2" value="7.15" lower_limit="5.7" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.4" upper_limit="6.6"/>
                    <measurement group_id="O2" value="5.15" lower_limit="4.3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 9 weeks.</time_frame>
      <desc>The definition of adverse event (AE) and/or serious adverse event used to collect AE information is the same as the ClinicalTrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Milnacipran</title>
          <description>Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):&#xD;
Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated and target accrual was unmet due to pre-screening exclusion criteria: 1) excluded concomitant medicines; and 2) patients who had prediabetes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas H. Brannagan, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>(212) 305-0405</phone>
      <email>tb2325@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

